hit counter script

Ri 2 Form 2 Why Ri 2 Form 2 Had Been So Popular Till Now?

Pennisi, E. Bioinformatics. Gene counters attempt to get the appropriate answer. Science 301, 1040–1041 (2003).

ri 1040 form 2020 Rhode Island Tax Forms and Instructions for 2 (Form RI-2)

Rhode Island Tax Forms and Instructions for 2 (Form RI-2) | ri 1040 form 2020

CAS  PubMed  Google Scholar 

Lander, E. S. et al. Antecedent sequencing and appraisal of the beastly genome. Attributes 409, 860–921 (2001).

CAS  PubMed  Google Scholar 

Venter, J. C. et al. The arrangement of the beastly genome. Science 291, 1304–1351 (2001).

CAS  PubMed  Google Scholar 

Reichert, J. M. Trends in development and approval times for new assay in the United States. Attributes Rev. Biologic Discov. 2, 695–702 (2003).

CAS  Google Scholar 

Slaff, J., Jacobson, D., Tillman, C. R., Curington, C. & Toskes, P. Protease-specific abolishment of pancreatic exocrine secretion. Gastroenterology 87, 44–52 (1984).

CAS  PubMed  Google Scholar 

Brown, A., Hughes, M., Tenner, S. & Banks, P. A. Does pancreatic agitator supplementation abate affliction in patients with abiding pancreatitis: a meta-analysis. Am. J. Gastroenterol. 92, 2032–2035 (1997).

CAS  PubMed  Google Scholar 

American Thoracic Society. Guidelines for the access to the accommodating with astringent ancestral α-1-antitrypsin deficiency. Am. Rev. Respir. Dis. 140, 1494–1497 (1989).

Dirksen, A. et al. A randomized analytic balloon of α(1)-antitrypsin accession therapy. Am. J. Respir. Crit. Affliction Med. 160, 1468–1472 (1999).

CAS  PubMed  Google Scholar 

Mason, H. S., Warzecha, H., Mor, T. & Arntzen, C. J. Edible bulb vaccines: applications for antibacterial and ameliorative atomic medicine. Trends Mol. Med. 8, 324–329 (2002).

CAS  PubMed  Google Scholar 

Wurm, F. & Bernard, A. Large-scale abrupt announcement in beastly beef for recombinant protein production. Curr. Opin. Biotechnol. 10, 156–159 (1999).

CAS  PubMed  Google Scholar 

Zoller, M. J. New atomic assay methods for protein engineering. Curr. Opin. Biotechnol. 2, 526–531 (1991).

CAS  PubMed  Google Scholar 

Brannigan, J. A. & Wilkinson, A. J. Protein engineering 20 years on. Attributes Rev. Mol. Corpuscle Biol. 3, 964–970 (2002).

CAS  Google Scholar 

Watson, J. D., Gilman, M., Witkowksi, J. & Zoller, M. in Recombinant DNA 453–470 (Scientific American Books, New York, 1992).

Google Scholar 

Egrie, J. C. & Browne, J. K. Development and assuming of atypical erythropoiesis aesthetic protein (NESP). Br. J. Blight 84 (Suppl. 1), 3–10 (2001).

CAS  PubMed  PubMed Central  Google Scholar 

Golan, D. E. et al. Principles of Pharmacology: The Pathophysiologic Basis of Biologic Assay 2nd edn (Lippincott Williams & Wilkins, Philadelphia, 2007).

Google Scholar 

Banting, F. G., Best, C. H., Collip, J. B., Campbell, W. R. & Fletcher, A. A. Pancreatic extracts in the assay of diabetes mellitus: basic report. 1922. CMAJ 145, 1281–1286 (1991).

CAS  PubMed  PubMed Central  Google Scholar 

Goeddel, D. V. et al. Announcement in Escherichia coli of chemically actinic genes for beastly insulin. Proc. Natl Acad. Sci. USA 76, 106–110 (1979).

CAS  PubMed  Google Scholar 

Clark, A. J. et al. Biosynthetic beastly insulin in the assay of diabetes. A double-blind crossover balloon in accustomed diabetic patients. Lancet 2, 354–357 (1982).

CAS  PubMed  Google Scholar 

Keen, H. et al. Beastly insulin produced by recombinant DNA technology: assurance and hypoglycaemic authority in advantageous men. Lancet 2, 398–401 (1980).

CAS  PubMed  Google Scholar 

Richter, B. & Neises, G. ‘Human’ insulin adjoin beastly insulin in bodies with diabetes mellitus. Cochrane Database Syst. Rev. 1, CD003816 (2003).

Google Scholar 

Morales, L. E. Gaucher’s disease: a review. Ann. Pharmacother. 30, 381–388 (1996).

CAS  PubMed  Google Scholar 

Niederau, C. & Haussinger, D. Gaucher’s disease: a assay for the internist and hepatologist. Hepatogastroenterology 47, 984–997 (2000).

CAS  PubMed  Google Scholar 

Whittington, R. & Goa, K. L. Alglucerase. A assay of its ameliorative use in Gaucher’s disease. Drugs 44, 72–93 (1992).

CAS  PubMed  Google Scholar 

Grabowski, G. A. et al. Agitator assay in blazon 1 Gaucher disease: allusive ability of mannose-terminated glucocerebrosidase from accustomed and recombinant sources. Ann. Intern. Med. 122, 33–39 (1995).

CAS  PubMed  Google Scholar 

Barton, N. W. et al. Backup assay for affiliated agitator absence — macrophage-targeted glucocerebrosidase for Gaucher’s disease. N. Engl. J. Med. 324, 1464–1470 (1991).

CAS  PubMed  Google Scholar 

Rosado, J. L., Solomons, N. W., Lisker, R. & Bourges, H. Agitator backup assay for primary developed lactase deficiency. Able abridgement of lactose malabsorption and milk bent by absolute accession of β-galactosidase to milk at mealtime. Gastroenterology 87, 1072–1082 (1984).

CAS  PubMed  Google Scholar 

Abildgaard, C. F. et al. Assay of hemophilia with glycine-precipitated agency 8. N. Engl. J. Med. 275, 471–475 (1966).

CAS  PubMed  Google Scholar 

Bray, G. L. et al. A multicenter abstraction of recombinant agency VIII (recombinate): safety, efficacy, and inhibitor accident in ahead basic patients with hemophilia A. The Recombinate Abstraction Group. Claret 83, 2428–2435 (1994).

CAS  PubMed  Google Scholar 

Roth, D. A. et al. Beastly recombinant agency IX: assurance and ability studies in hemophilia B patients ahead advised with plasma-derived agency IX concentrates. Claret 98, 3600–3606 (2001).

CAS  PubMed  Google Scholar 

Haase, M. Beastly recombinant agency IX: assurance and ability studies in hemophilia B patients ahead advised with plasma-derived agency IX concentrates. Claret 100, 4242 (2002).

CAS  PubMed  Google Scholar 

Kasper, D. K. et al. Harrison’s Principles of Internal Anesthetic 16th edn (McGraw-Hill Professional, New York, 2004).

Google Scholar 

Benz, R. L., Pressman, M. R., Hovick, E. T. & Peterson, D. D. A basic abstraction of the furnishings of alteration of anemia with recombinant beastly erythropoietin assay on sleep, beddy-bye disorders, and daytime apathy in hemodialysis patients (The SLEEPO study). Am. J. Kidney Dis. 34, 1089–1095 (1999).

CAS  PubMed  Google Scholar 

Corwin, H. L. et al. Ability of recombinant beastly erythropoietin in alarmingly ill patients: a randomized controlled trial. JAMA 288, 2827–2835 (2002).

CAS  PubMed  Google Scholar 

Evans, R. W., Rader, B. & Manninen, D. L. The affection of action of hemodialysis recipients advised with recombinant beastly erythropoietin. Cooperative Multicenter EPO Analytic Balloon Group. JAMA 263, 825–830 (1990).

CAS  PubMed  Google Scholar 

Levin, N. W., Lazarus, J. M. & Nissenson, A. R. National Cooperative rHu erythropoietin abstraction in patients with abiding renal abortion — an acting report. The National Cooperative rHu Erythropoietin Abstraction Group. Am. J. Kidney Dis. 22, 3–12 (1993).

CAS  PubMed  Google Scholar 

Miles, S. The use of hematopoietic advance factors in alleviative HIV infection. Curr. Opin. Hematol. 2, 227–233 (1995).

CAS  PubMed  Google Scholar 

Lieschke, G. J. & Burgess, A. W. Granulocyte colony-stimulating agency and granulocyte-macrophage colony-stimulating agency (2). N. Engl. J. Med. 327, 99–106 (1992).

CAS  PubMed  Google Scholar 

Tepler, I. et al. A randomized placebo-controlled balloon of recombinant beastly interleukin-11 in blight patients with astringent thrombocytopenia due to chemotherapy. Claret 87, 3607–3614 (1996).

CAS  PubMed  Google Scholar 

Out, H. J., Driessen, S. G., Mannaerts, B. M. & Coelingh Bennink, H. J. Recombinant follicle-stimulating hormone (follitropin beta, Puregon) yields college abundance ante in in vitro fertilization than urinary gonadotropins. Fertil. Steril. 68, 138–142 (1997).

CAS  PubMed  Google Scholar 

Van Wely, M., Westergaard, L. G., Bossuyt, P. M. & Van der Veen, F. Beastly menopausal gonadotropin adjoin recombinant corpuscle dispatch hormone for ovarian dispatch in assisted changeable cycles. Cochrane Database Syst. Rev. 1, CD003973 (2003).

Google Scholar 

Ludwig, M., Doody, K. J. & Doody, K. M. Use of recombinant beastly chorionic gonadotropin in ovulation induction. Fertil. Steril. 79, 1051–1059 (2003).

PubMed  Google Scholar 

A allegory of connected beverage of alteplase with double-bolus administering for astute myocardial infarction. The Connected Beverage adjoin Double-Bolus Administering of Alteplase (COBALT) Investigators. N. Engl. J. Med. 337, 1124–1130 (1997).

Clark, W. M. et al. Recombinant tissue-type plasminogen activator (Alteplase) for ischemic achievement 3 to 5 hours afterwards affirmation onset. The ATLANTIS Study: a randomized controlled trial. alteplase thrombolysis for astute noninterventional assay in ischemic stroke. JAMA 282, 2019–2026 (1999).

CAS  PubMed  Google Scholar 

Goldhaber, S. Z. et al. Alteplase adjoin heparin in astute pulmonary embolism: randomised balloon assessing right-ventricular action and pulmonary perfusion. Lancet 341, 507–511 (1993).

CAS  PubMed  Google Scholar 

Albers, G. W. et al. Intravenous tissue-type plasminogen activator for assay of astute stroke: the Accepted Assay with Alteplase to Reverse Achievement (STARS) study. JAMA 283, 1145–1150 (2000).

CAS  PubMed  Google Scholar 

Katzan, I. L. et al. Use of tissue-type plasminogen activator for astute ischemic stroke: the Cleveland breadth experience. JAMA 283, 1151–1158 (2000).

CAS  PubMed  Google Scholar 

No authors listed. Randomised, double-blind allegory of reteplase double-bolus administering with streptokinase in astute myocardial infarction (INJECT): balloon to investigate equivalence. All-embracing Joint Ability Allegory of Thrombolytics. Lancet 346, 329–336 (1995).

No authors listed. A allegory of reteplase with alteplase for astute myocardial infarction. The Global Use of Strategies to Accessible Occluded Coronary Arteries (GUSTO III) Investigators. N. Engl. J. Med. 337, 1118–1123 (1997).

No authors listed. Single-bolus tenecteplase compared with front-loaded alteplase in astute myocardial infarction: the ASSENT-2 double-blind randomised trial. Assessment of the Assurance and Ability of a New Thrombolytic Investigators. Lancet 354, 716–722 (1999).

No authors listed. Ability and assurance of tenecteplase in aggregate with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised balloon in astute myocardial infarction. Lancet 358, 605–613 (2001).

Shapiro, A. D., Gilchrist, G. S., Hoots, W. K., Cooper, H. A. & Gastineau, D. A. Prospective, randomised balloon of two doses of rFVIIa (NovoSeven) in haemophilia patients with inhibitors ability surgery. Thromb. Haemost. 80, 773–778 (1998).

CAS  PubMed  Google Scholar 

Hedner, U. Dosing with recombinant agency VIIa based on accepted evidence. Semin. Hematol. 41, 35–39 (2004).

CAS  PubMed  Google Scholar 

Bernard, G. R. et al. Ability and assurance of recombinant beastly activated protein C for astringent sepsis. N. Engl. J. Med. 344, 699–709 (2001).

CAS  PubMed  Google Scholar 

Dhainaut, J. F., Yan, S. B. & Claessens, Y. E. Protein C/activated protein C pathway: overview of analytic balloon after-effects in astringent sepsis. Crit. Affliction Med. 32, S194–S201 (2004).

CAS  PubMed  Google Scholar 

Burke, J. F. & Golden, T. A analytic appraisal of enzymatic debridement with papain-urea-chlorophyllin ointment. Am. J. Surg. 95, 828–842 (1958).

CAS  PubMed  Google Scholar 

Boxer, A. M., Gottesman, N., Bernstein, H. & Mandl, I. Debridement of dermal ulcers and decubiti with collagenase. Geriatrics 24, 75–86 (1969).

CAS  PubMed  Google Scholar 

Rao, D. B., Sane, P. G. & Georgiev, E. L. Collagenase in the assay of dermal and decubitus ulcers. J. Am. Geriatr. Soc. 23, 22–30 (1975).

CAS  PubMed  Google Scholar 

Fuchs, H. J. et al. Effect of aerosolized recombinant beastly DNase on exacerbations of respiratory affection and on pulmonary action in patients with cystic fibrosis. The Pulmozyme Abstraction Group. N. Engl. J. Med. 331, 637–642 (1994).

CAS  PubMed  Google Scholar 

Holle, L. M. Pegaspargase: an alternative? Ann. Pharmacother. 31, 616–624 (1997).

CAS  PubMed  Google Scholar 

Clavell, L. A. et al. Four-agent consecration and accelerated asparaginase assay for assay of adolescence astute lymphoblastic leukemia. N. Engl. J. Med. 315, 657–663 (1986).

CAS  PubMed  Google Scholar 

Greinacher, A. et al. Recombinant hirudin (lepirudin) provides safe and able anticoagulation in patients with heparin-induced thrombocytopenia: a -to-be study. Circulation 99, 73–80 (1999).

CAS  PubMed  Google Scholar 

Eriksson, B. I. et al. A allegory of recombinant hirudin with a low-molecular-weight heparin to anticipate thromboembolic complications afterwards absolute hip replacement. N. Engl. J. Med. 337, 1329–1335 (1997).

CAS  PubMed  Google Scholar 

Rogers, L. Q. & Lutcher, C. L. Streptokinase assay for abysmal attitude thrombosis: a absolute assay of the English literature. Am. J. Med. 88, 389–395 (1990).

CAS  PubMed  Google Scholar 

Kennedy, J. W., Ritchie, J. L., Davis, K. B. & Fritz, J. K. Western Washington randomized balloon of intracoronary streptokinase in astute myocardial infarction. N. Engl. J. Med. 309, 1477–1482 (1983).

CAS  PubMed  Google Scholar 

Anderson, J. L. et al. A randomized balloon of intracoronary streptokinase in the assay of astute myocardial infarction. N. Engl. J. Med. 308, 1312–1318 (1983).

CAS  PubMed  Google Scholar 

No authors listed. An all-embracing randomized balloon comparing four thrombolytic strategies for astute myocardial infarction. The GUSTO investigators. N. Engl. J. Med. 329, 673–682 (1993).

Clark, M. Antibiotic humanization: a case of the ‘Emperor’s new clothes’? Immunol. Today 21, 397–402 (2000).

CAS  PubMed  Google Scholar 

Mease, P. J. et al. Etanercept in the assay of psoriatic arthritis and psoriasis: a randomised trial. Lancet 356, 385–390 (2000).

CAS  PubMed  Google Scholar 

Weinblatt, M. E. et al. A balloon of etanercept, a recombinant bump afterlife agency receptor:Fc admixture protein, in patients with rheumatoid arthritis accepting methotrexate. N. Engl. J. Med. 340, 253–259 (1999).

CAS  PubMed  Google Scholar 

Gorman, J. D., Sack, K. E. & Davis, J. C. Jr. Assay of ankylosing spondylitis by inhibition of bump afterlife agency α. N. Engl. J. Med. 346, 1349–1356 (2002).

CAS  PubMed  Google Scholar 

Lipsky, P. E. et al. Infliximab and methotrexate in the assay of rheumatoid arthritis. Anti-Tumor Afterlife Agency Balloon in Rheumatoid Arthritis with Accessory Assay Abstraction Group. N. Engl. J. Med. 343, 1594–1602 (2000).

CAS  PubMed  Google Scholar 

Maini, R. et al. Infliximab (chimeric anti-tumour afterlife agency α monoclonal antibody) adjoin placebo in rheumatoid arthritis patients accepting accessory methotrexate: a randomised appearance III trial. ATTRACT Abstraction Group. Lancet 354, 1932–1939 (1999).

CAS  PubMed  Google Scholar 

Present, D. H. et al. Infliximab for the assay of fistulas in patients with Crohn’s disease. N. Engl. J. Med. 340, 1398–1405 (1999).

CAS  PubMed  Google Scholar 

No authors listed. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces assay from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Abstraction Group. Pediatrics 102, 531–537 (1998).

Meissner, H. C. & Long, S. S. Revised break for the use of palivizumab and respiratory syncytial virus allowed globulin intravenous for the blockage of respiratory syncytial virus infections. Pediatrics 112, 1447–1452 (2003).

PubMed  Google Scholar 

Matthews, T. et al. Enfuvirtide: the aboriginal assay to arrest the access of HIV-1 into host CD4 lymphocytes. Attributes Rev. Biologic Discov. 3, 215–225 (2004).

CAS  Google Scholar 

Lazzarin, A. et al. Ability of enfuvirtide in patients adulterated with drug-resistant HIV-1 in Europe and Australia. N. Engl. J. Med. 348, 2186–2195 (2003).

CAS  PubMed  Google Scholar 

ri 1040 form 2020 Form RI-2 Download Fillable PDF or Fill Online Resident

Form RI-2 Download Fillable PDF or Fill Online Resident | ri 1040 form 2020

Lalezari, J. P. et al. Enfuvirtide, an HIV-1 admixture inhibitor, for drug-resistant HIV infection in North and South America. N. Engl. J. Med. 348, 2175–2185 (2003).

CAS  PubMed  Google Scholar 

McLaughlin, P. et al. Rituximab chimeric anti-CD20 monoclonal antibiotic assay for relapsed blah lymphoma: bisected of patients acknowledge to a four-dose assay program. J. Clin. Oncol. 16, 2825–2833 (1998).

CAS  PubMed  Google Scholar 

Maloney, D. G. et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibiotic assay in patients with relapsed low-grade non-Hodgkin’s lymphoma. Claret 90, 2188–2195 (1997).

CAS  Google Scholar 

Coiffier, B. et al. CHOP chemotherapy additional rituximab compared with CHOP abandoned in aged patients with broadcast large-B-cell lymphoma. N. Engl. J. Med. 346, 235–242 (2002).

CAS  PubMed  Google Scholar 

Cunningham, D. et al. Cetuximab monotherapy and cetuximab additional irinotecan in irinotecan-refractory metastatic colorectal cancer. N. Engl. J. Med. 351, 337–345 (2004).

CAS  PubMed  Google Scholar 

Slamon, D. J. et al. Use of chemotherapy additional a monoclonal antibiotic adjoin HER2 for metastatic breast blight that overexpresses HER2. N. Engl. J. Med. 344, 783–792 (2001).

CAS  PubMed  Google Scholar 

Vogel, C. L. et al. Ability and assurance of trastuzumab as a distinct abettor in first-line assay of HER2-overexpressing metastatic breast cancer. J. Clin. Oncol. 20, 719–726 (2002).

CAS  PubMed  PubMed Central  Google Scholar 

Valabrega, G. M., Montemurro, F. & Aglietta, M. Trastuzumab: apparatus of action, attrition and approaching perspectives in HER2-overexpressing breast cancer. Ann. Oncol. 18, 977–984 (2007).

CAS  PubMed  Google Scholar 

Sievers, E. L. et al. Ability and assurance of gemtuzumab ozogamicin in patients with CD33-positive astute myeloid leukemia in aboriginal relapse. J. Clin. Oncol. 19, 3244–3254 (2001).

CAS  PubMed  Google Scholar 

Giles, F., Estey, E. & O’Brien, S. Gemtuzumab ozogamicin in the assay of astute myeloid leukemia. Blight 98, 2095–2104 (2003).

CAS  PubMed  Google Scholar 

Witzig, T. E. et al. Randomized controlled balloon of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy adjoin rituximab immunotherapy for patients with relapsed or adverse low-grade, follicular, or adapted B-cell non-Hodgkin’s lymphoma. J. Clin. Oncol. 20, 2453–2463 (2002).

CAS  PubMed  Google Scholar 

Ho, V. T. et al. Assurance and ability of denileukin diftitox in patients with steroid-refractory astute graft-versus-host ache afterwards allogeneic hematopoietic arbor corpuscle transplantation. Claret 104, 1224–1226 (2004).

CAS  PubMed  Google Scholar 

Olsen, E. et al. Pivotal appearance III balloon of two dosage levels of denileukin diftitox for the assay of cutaneous T-cell lymphoma. J. Clin. Oncol. 19, 376–388 (2001).

CAS  PubMed  Google Scholar 

Phelan, A., Elliott, G. & O’Hare, P. Intercellular commitment of anatomic p53 by the herpesvirus protein VP22. Attributes Biotechnol. 16, 440–443 (1998).

CAS  Google Scholar 

Francis, J. W., Hosler, B. A., Brown, R. H. Jr & Fishman, P. S. CuZn superoxide dismutase (SOD-1):tetanus adulteration fragment C amalgam protein for targeted commitment of SOD-1 to neuronal cells. J. Biol. Chem. 270, 15434–15442 (1995).

CAS  PubMed  Google Scholar 

Szmuness, W. et al. Hepatitis B vaccine: affirmation of ability in a controlled analytic balloon in a high-risk citizenry in the United States. N. Engl. J. Med. 303, 833–841 (1980).

CAS  PubMed  Google Scholar 

Crosnier, J. et al. Randomised placebo-controlled balloon of hepatitis B apparent antigen vaccine in French haemodialysis units: I, Medical staff. Lancet 1, 455–459 (1981).

CAS  PubMed  Google Scholar 

Sigal, L. H. et al. A vaccine consisting of recombinant Borrelia burgdorferi outer-surface protein A to anticipate Lyme disease. Recombinant Outer-Surface Protein A Lyme Ache Vaccine Abstraction Consortium. N. Engl. J. Med. 339, 216–222 (1998).

CAS  PubMed  Google Scholar 

Steere, A. C. et al. Vaccination adjoin Lyme ache with recombinant Borrelia burgdorferi outer-surface lipoprotein A with adjuvant. Lyme Ache Vaccine Abstraction Group. N. Engl. J. Med. 339, 209–215 (1998).

CAS  PubMed  Google Scholar 

Shi, L. et al. Gardasil: antibacterial beastly papillomavirus vaccine development — from bank top to bed-side. Clin. Pharm. Ther. 81, 259–264 (2007).

CAS  Google Scholar 

MacKenzie, I. Z. et al. Ability and assurance of a new, chromatographically antiseptic rhesus (D) immunoglobulin. Eur. J. Obstet. Gynecol. Reprod. Biol. 117, 154–161 (2004).

CAS  PubMed  Google Scholar 

McCormick, A. A. et al. Rapid assembly of specific vaccines for lymphoma by announcement of the tumor-derived single-chain Fv epitopes in tobacco plants. Proc. Natl Acad. Sci. USA 96, 703–708 (1999).

CAS  PubMed  Google Scholar 

Campos-Neto, A. et al. Appraisal of DPPD, a distinct recombinant Mycobacterium tuberculosis protein as an another antigen for the Mantoux test. Tuberculosis (Edinb.) 81, 353–358 (2001).

CAS  Google Scholar 

Coler, R. N. et al. Cloning of a Mycobacterium tuberculosis gene encoding a purifed protein acquired protein that elicits able tuberculosis-specific delayed-type hypersensitivity. J. Infect. Dis. 182, 224–233 (2000).

CAS  PubMed  Google Scholar 

Duchin, J. S., Jereb, J. A., Nolan, C. M., Smith, P. & Onorato, I. M. Allegory of sensitivities to two commercially accessible tuberculin bark assay reagents in bodies with contempo tuberculosis. Clin. Infect. Dis. 25, 661–663 (1997).

CAS  PubMed  Google Scholar 

Ranke, M. B. et al. Testing with advance hormone-releasing agency (GRF(1–29)NH2) and somatomedin C abstracts for the appraisal of advance hormone deficiency. Eur. J. Pediatr. 145, 485–492 (1986).

CAS  PubMed  Google Scholar 

Ghigo, E. et al. New access to the assay of advance hormone absence in adults. Eur. J. Endocrinol. 134, 352–356 (1996).

CAS  PubMed  Google Scholar 

Ladenson, P. W. et al. Allegory of administering of recombinant beastly thyrotropin with abandonment of thyroid hormone for radioactive iodine scanning in patients with thyroid carcinoma. N. Engl. J. Med. 337, 888–896 (1997).

CAS  PubMed  Google Scholar 

Meier, C. A. et al. Diagnostic use of recombinant beastly thyrotropin in patients with thyroid blight (phase I/II study). J. Clin. Endocrinol. Metab. 78, 188–196 (1994).

CAS  PubMed  Google Scholar 

Taillefer, R., Edell, S., Innes, G. & Lister-James, J. Astute thromboscintigraphy with Tc-99m-apcitide: after-effects of the appearance 3 multicenter analytic balloon comparing Tc-99m-apcitide scintigraphy with adverse venography for imaging astute DVT. J. Nucl. Med. 41, 1214–1223 (2000).

CAS  PubMed  Google Scholar 

Sodee, D. B. et al. Multicenter ProstaScint imaging allegation in 2154 patients with prostate cancer. Urology 56, 988–993 (2000).

CAS  PubMed  Google Scholar 

Urnovitz, H. B., Sturge, J. C. & Gottfried, T. D. Increased acuteness of HIV-1 antibiotic detection. Attributes Med. 3, 1258 (1997).

CAS  PubMed  Google Scholar 

Van de Perre, P. et al. Postnatal manual of beastly immunodeficiency virus blazon 1 from mother to infant. A -to-be accomplice abstraction in Kigali, Rwanda. N. Engl. J. Med. 325, 593–598 (1991).

CAS  PubMed  Google Scholar 

Busch, M. P. et al. Appraisal of buried claret donations for beastly immunodeficiency virus blazon 1 infection by ability and DNA addition of affiliated cells. N. Engl. J. Med. 325, 1–5 (1991).

CAS  PubMed  Google Scholar 

Van der Poel, C. L. et al. Confirmation of hepatitis C virus infection by new four-antigen recombinant immunoblot assay. Lancet 337, 317–319 (1991).

CAS  PubMed  Google Scholar 

Soffredini, R. et al. Increased apprehension of antibiotic to hepatitis C virus in renal displace patients by third-generation assays. Am. J. Kidney Dis. 28, 437–440 (1996).

CAS  PubMed  Google Scholar 

Putney, S. D. & Burke, P. A. Improving protein assay with sustained-release formulations. Attributes Biotech. 16, 153–157 (1998).

CAS  Google Scholar 

Mahmood, I. & Green, M. D. Pharmacokinetic and pharmacodynamic considerations in the development of ameliorative proteins. Clin. Pharmacokinet. 44, 331–347 (2005).

CAS  PubMed  Google Scholar 

Schellekens, H. Bioequivalence and the immunogenicity of biopharmaceuticals. Attributes Rev. Biologic Discov. 1, 457–462 (2002).

CAS  Google Scholar 

Peerlinck, K., Arnout, J., Gilles, J. G., Saintremy, J. M. & Vermylen, J. A college than accepted accident of factor-VIII inhibitors in multitransfused hemophilia-A patients advised with an average abstention pasteurized factor-VIII concentrate. Thromb. Haemost. 69, 115–118 (1993).

CAS  PubMed  Google Scholar 

Gilles, J. G., Arnout, J., Vermylen, J. & Saint-Remy, J. M. Anti-factor VIII antibodies of hemophiliac patients are frequently directed appear adorning determinants and do not display isotypic restriction. Claret 82, 2452–2461 (1993).

CAS  PubMed  Google Scholar 

Mascelli, M. A. et al. Molecular, biologic, and pharmacokinetic backdrop of monoclonal antibodies: appulse of these ambit on aboriginal analytic development. J. Clin. Pharm. 47, 553–565 (2007).

CAS  Google Scholar 

Reichert, J. M. & Valge-Archer, V. E. Development trends for monoclonal antibiotic blight therapeutics. Attributes Rev. Biologic Discov. 6, 349–356 (2007).

CAS  Google Scholar 

Bussel, J. B. et al. AMG 531, a thrombopoiesis-stimulating protein, for abiding ITP. N. Engl. J. Med. 355, 1672–1681 (2006).

CAS  PubMed  Google Scholar 

Li, J. Z. et al. Thrombocytopenia acquired by the development of antibodies to thrombopoietin. Claret 98, 3241–3248 (2001).

CAS  PubMed  Google Scholar 

Basser, R. L. et al. Development of pancytopenia with acrid antibodies to thrombopoietin afterwards multicycle chemotherapy accurate by megakaryocyte advance and development factor. Claret 99, 2599–2602 (2002).

CAS  PubMed  Google Scholar 

Walsh, C. T. Posttranslational Modification of Proteins: Expanding Nature’s Inventory (Roberts & Company, Colorado, 2005).

Google Scholar 

Frokjaer, S. & Otzen, D. E. Protein biologic stability: a conception challenge. Attributes Rev. Biologic Discov. 4, 298–306 (2005).

CAS  Google Scholar 

Fowler, S. B. et al. Rational architecture of aggregation-resistant bioactive peptides: reengineering beastly calcitonin. Proc. Natl Acad. Sci. USA 102, 10105–10110 (2005).

CAS  PubMed  Google Scholar 

Dinnis, D. M. & James, D. C. Engineering beastly corpuscle factories for bigger recombinant monoclonal antibiotic production: acquaint from nature? Biotechnol. Bioeng. 91, 180–189 (2005).

CAS  Google Scholar 

Datar, R. V., Cartwright, T. & Rosen, C. G. Process economics of beastly corpuscle and bacterial fermentations: a case abstraction appraisal of tissue plasminogen activator. Biotechnology (NY) 11, 349–357 (1993).

CAS  Google Scholar 

Lillico, S. G., McGrew, M. J., Sherman, A. & Sang, H. M. Transgenic chickens as bioreactors for protein-based drugs. Biologic Discov. Today 10, 191–196 (2005).

CAS  PubMed  Google Scholar 

Pogue, G. P., Lindbo, J. A., Garger, S. J. & Fitzmaurice, W. P. Making an accessory from an enemy: bulb virology and the new agriculture. Annu. Rev. Phytopathol. 40, 45–74 (2002).

CAS  PubMed  Google Scholar 

Micheletti, M. et al. Aqueous bond in annoyed bioreactors: implications for scale-up predictions for microlitre-scale microbial and beastly corpuscle cultures. Chem. Eng. Sci. 61 (2006).

CAS  Google Scholar 

Gross, M. L. Ethics, policy, and attenuate abiogenetic disorders: the case of Gaucher ache in Israel. Theor. Med. Bioeth. 23, 151–170 (2002).

PubMed  Google Scholar 

Finkelstein, B. S. et al. Effect of advance hormone assay on acme in accouchement with idiopathic abbreviate stature: a meta-analysis. Arch. Pediatr. Adolesc. Med. 156, 230–240 (2002).

PubMed  Google Scholar 

Hokken-Koelega, A. C. et al. Advance hormone assay in growth-retarded adolescents afterwards renal transplant. Lancet 343, 1313–1317 (1994).

CAS  PubMed  Google Scholar 

Howrie, D. L. Advance hormone for the assay of advance abortion in children. Clin. Pharm. 6, 283–291 (1987).

CAS  PubMed  Google Scholar 

Salomon, F., Cuneo, R. C., Hesp, R. & Sonksen, P. H. The furnishings of assay with recombinant beastly advance hormone on anatomy agreement and metabolism in adults with advance hormone deficiency. N. Engl. J. Med. 321, 1797–1803 (1989).

CAS  PubMed  Google Scholar 

Thorner, M. O. et al. The assay of advance hormone absence (GHD) in adults. J. Clin. Endocrinol. Metab. 80, 3097–3098 (1995).

CAS  PubMed  Google Scholar 

Graham, J., Muhsin, M. & Kirkpatrick, P. Cetuximab. Attributes Rev. Biologic Discov. 3, 549–550 (2004).

Google Scholar 

Goldberg, R. M. & Kirkpatrick, P. Cetuximab. Attributes Rev. Biologic Discov. 4 (Suppl. 1) S10–S11 (2005).

Google Scholar 

Saltz, L. B. et al. Appearance II balloon of cetuximab in patients with adverse colorectal blight that expresses the epidermal advance agency receptor. J. Clin. Oncol. 22, 1201–1208 (2004).

CAS  PubMed  Google Scholar 

Warrier, I. et al. Agency IX inhibitors and anaphylaxis in hemophilia B. J. Pediatr. Hematol. Oncol. 19, 23–27 (1997).

CAS  PubMed  Google Scholar 

Thorland, E. C. et al. Anaphylactic acknowledgment to agency IX backup assay in haemophilia B patients: complete gene deletions advise the accomplished risk. Haemophilia 5, 101–105 (1999).

CAS  PubMed  Google Scholar 

Rosenberg, R. D., Goldman, P., Bing, D. & Glass, J. Actions and interactions of antithrombin and heparin. N. Engl. J. Med. 292, 146–151 (1975).

CAS  PubMed  Google Scholar 

Mannucci, P. M., Boyer, C., Wolf, M., Tripodi, A. & Larrieu, M. J. Assay of complete antithrombin-III absence with concentrates. Br. J. Haematol. 50, 531–535 (1982).

CAS  PubMed  Google Scholar 

Moritz, B. et al. The ability and assurance of protein C apply (Human) vapor-heated in the assay of astringent complete protein C absence with or afterwards pupura fulminans. Claret 96, 53A–53A (2000).

Google Scholar 

Quattrin, T., Belanger, A., Bohannon, N. J. V. & Schwartz, S. L. Ability and assurance of inhaled insulin (Exubera) compared with subcutaneous insulin assay in patients with blazon 1 diabetes — after-effects of a 6-month, randomized, allusive trial. Diabetes Affliction 27, 2622–2627 (2004).

CAS  PubMed  Google Scholar 

Hollander, P. A. et al. Ability and assurance of inhaled insulin (Exubera) compared with subcutaneous insulin assay in patients with blazon 2 diabetes — after-effects of a 6-month, randomized, allusive trial. Diabetes Affliction 27, 2356–2362 (2004).

CAS  PubMed  Google Scholar 

Skyler, J. S. et al. Ability of inhaled beastly insulin in blazon 1 diabetes mellitus: a randomised proof-of-concept study. Lancet 357, 331–335 (2001).

CAS  PubMed  Google Scholar 

Edwards, D. A. et al. Ample absorptive particles for pulmonary biologic delivery. Science 276, 1868–1871 (1997).

CAS  PubMed  Google Scholar 

Hirsch, I. B. Biologic therapy: Insulin analogues. N. Engl. J. Med. 352, 174–183 (2005).

CAS  PubMed  Google Scholar 

Dreyer, M. et al. Ability and assurance of insulin glulisine in patients with blazon 1 diabetes. Horm. Metab. Res. 37, 702–707 (2005).

CAS  PubMed  Google Scholar 

Soran, H. & Younis, N. Insulin detemir: a new basal insulin analogue. Diabetes Obes. Metab. 8, 26–30 (2006).

CAS  PubMed  Google Scholar 

Thompson, R. G., Peterson, J., Gottlieb, A. & Mullane, J. Furnishings of pramlintide, an analog of beastly amylin, on claret glucose profiles in patients with IDDM — after-effects of a multicenter trial. Diabetes 46, 632–636 (1997).

CAS  PubMed  Google Scholar 

Backeljauw, P. F. & Underwood, L. E. Assay for 6.5–7.5 years with recombinant insulin-like advance agency I in accouchement with advance hormone aloofness syndrome: a analytic assay centermost study. J. Clin. Endocrinol. Metab. 86, 1504–1510 (2001).

CAS  PubMed  PubMed Central  Google Scholar 

Kemp, S. F., Fowlkes, J. L. & Thrailkill, K. M. Ability and assurance of mecasermin rinfabate. Expert Opin. Biol. Ther. 6, 533–538 (2006).

CAS  Google Scholar 

Ho, M. W. & O’Brien, J. S. Gaucher’s disease: absence of ‘acid’ -glucosidase and reconstitution of agitator action in vitro. Proc. Natl Acad. Sci. USA 68, 2810–2813 (1971).

CAS  PubMed  Google Scholar 

Klinge, L. et al. Assurance and ability of recombinant acerbic α-glucosidase (rhGAA) in patients with classical baby Pompe disease: after-effects of a appearance II analytic trial. Neuromuscul. Disord. 15, 24–31 (2005).

CAS  PubMed  Google Scholar 

Scott, H. S. et al. Beastly α-L-iduronidase: cDNA abreast and expression. Proc. Natl Acad. Sci. USA 88, 9695–9699 (1991).

CAS  PubMed  Google Scholar 

Bach, G., Friedman, R., Weissmann, B. & Neufeld, E. F. The birthmark in the Hurler and Scheie syndromes: absence of α-L-iduronidase. Proc. Natl Acad. Sci. USA 69, 2048–2051 (1972).

CAS  PubMed  Google Scholar 

Kakkis, E. D. et al. Enzyme-replacement assay in mucopolysaccharidosis I. N. Engl. J. Med. 344, 182–188 (2001).

CAS  PubMed  Google Scholar 

Muenzer, J. et al. A appearance II/III analytic abstraction of agitator backup assay with idursulfase in mucopolysaccharidosis II (Hunter syndrome). Genet. Med. 8, 465–473 (2006).

CAS  PubMed  Google Scholar 

Hopwood, J. J., Bate, G. & Kirkpatrick, P. Galsulfase. Attributes Rev. Biologic Discov. 5, 101–102 (2006).

CAS  Google Scholar 

Eng., C. M. et al. Assurance and ability of recombinant beastly α-galactosidase A — backup assay in Fabry’s disease. N. Engl. J. Med. 345, 9–16 (2001).

CAS  PubMed  Google Scholar 

Schiffmann, R. et al. Agitator backup assay in Fabry disease: a randomized controlled trial. JAMA 285, 2743–2749 (2001).

CAS  PubMed  Google Scholar 

Society, A. T. Guidelines for the access to the accommodating with astringent ancestral a-1-antitrypsin deficiency. Am. Rev. Respir. Dis. 140, 1494–1497 (1989).

Google Scholar 

Hershfield, M. S. et al. Assay of adenosine deaminase absence with polyethylene glycol-modified adenosine deaminase. N. Engl. J. Med. 316, 589–596 (1987).

CAS  PubMed  Google Scholar 

Ochs, H. D. & Pinciaro, P. J. Octagam 5%, an intravenous IgG product, is active and able-bodied acceptable in accommodation with primary immunodeficiency diseases. J. Clin. Immunol. 24, 309–314 (2004).

CAS  PubMed  Google Scholar 

Finfer, S. et al. A allegory of albumin and acrid for aqueous resuscitation in the accelerated affliction unit. N. Engl. J. Med. 350, 2247–2256 (2004).

CAS  PubMed  Google Scholar 

No authors listed. Association amid recombinant beastly erythropoietin and affection of action and exercise accommodation of patients accepting haemodialysis. Canadian Erythropoietin Abstraction Group. BMJ 300, 573–578 (1990).

Laupacis, A. Changes in affection of action and anatomic accommodation in hemodialysis patients advised with recombinant beastly erythropoietin. The Canadian Erythropoietin Abstraction Group. Semin. Nephrol. 10, 11–19 (1990).

CAS  PubMed  Google Scholar 

Heil, G. et al. A randomized, double-blind, placebo-controlled, appearance III abstraction of filgrastim in absolution consecration and alliance assay for adults with de novo astute myeloid leukemia. Claret 90, 4710–4718 (1997).

CAS  PubMed  Google Scholar 

Tarlatzis, B. et al. The use of recombinant beastly LH (lutropin alfa) in the backward dispatch appearance of assisted reproduction cycles: a double-blind, randomized, -to-be study. Hum. Reprod. 21, 90–94 (2006).

CAS  PubMed  Google Scholar 

Cirelli, R. & Tyring, S. K. Interferons in beastly papillomavirus infections. Antiviral Res. 24, 191–204 (1994).

CAS  PubMed  Google Scholar 

Lindsay, K. L. Assay of hepatitis C: overview. Hepatology 26, 71S–77S (1997).

CAS  PubMed  Google Scholar 

Tong, M. J. et al. Assay of abiding hepatitis C with accord interferon: a multicenter, randomized, controlled trial. Accord Interferon Abstraction Group. Hepatology 26, 747–754 (1997).

CAS  PubMed  Google Scholar 

Suzuki, H. & Tango, T. A multicenter, randomized, controlled analytic balloon of interferon alfacon-1 in allegory with lymphoblastoid interferon-α in patients with high-titer abiding hepatitis C virus infection. Hepatol. Res. 22, 1–12 (2002).

CAS  PubMed  Google Scholar 

van Zonneveld, M. et al. Abiding aftereffect of α-interferon assay of patients with abiding hepatitis B. Hepatology 39, 804–810 (2004).

CAS  PubMed  Google Scholar 

Giannini, E. et al. Abiding chase up of abiding hepatitis C patients afterwards α-interferon treatment: a anatomic study. J. Gastroenterol. Hepatol. 16, 399–405 (2001).

CAS  PubMed  Google Scholar 

Smalley, R. V. et al. Interferon α accumulated with cytotoxic chemotherapy for patients with non-Hodgkin’s lymphoma. N. Engl. J. Med. 327, 1336–1341 (1992).

CAS  PubMed  Google Scholar 

Quesada, J. R. et al. Assay of bearded corpuscle leukemia with recombinant α-interferon. Claret 68, 493–497 (1986).

CAS  PubMed  Google Scholar 

Allan, N. C., Richards, S. M. & Shepherd, P. C. UK Medical Assay Council randomised, multicentre balloon of interferon-α n1 for abiding myeloid leukaemia: bigger adaptation irrespective of cytogenetic response. The UK Medical Assay Council’s Working Parties for Ameliorative Trials in Developed Leukaemia. Lancet 345, 1392–1397 (1995).

CAS  PubMed  Google Scholar 

No authors listed. Interferon α-2a as compared with accepted chemotherapy for the assay of abiding myeloid leukemia. The Italian Cooperative Abstraction Group on Abiding Myeloid Leukemia. N. Engl. J. Med. 330, 820–825 (1994).

Misiani, R. et al. Interferon α-2a assay in cryoglobulinemia associated with hepatitis C virus. N. Engl. J. Med. 330, 751–756 (1994).

CAS  PubMed  Google Scholar 

Fried, M. W. et al. Peginterferon α-2a additional ribavirin for abiding hepatitis C virus infection. N. Engl. J. Med. 347, 975–982 (2002).

CAS  PubMed  Google Scholar 

Zeuzem, S. et al. Peginterferon α-2a in patients with abiding hepatitis C. N. Engl. J. Med. 343, 1666–1672 (2000).

CAS  PubMed  Google Scholar 

Heathcote, E. J. et al. Peginterferon α-2a in patients with abiding hepatitis C and cirrhosis. N. Engl. J. Med. 343, 1673–1680 (2000).

CAS  PubMed  Google Scholar 

Mandelli, F. et al. Maintenance assay with recombinant interferon α-2b in patients with assorted myeloma responding to accepted consecration chemotherapy. N. Engl. J. Med. 322, 1430–1434 (1990).

CAS  PubMed  Google Scholar 

Perrillo, R. P. et al. A randomized, controlled balloon of interferon α-2b abandoned and afterwards prednisone abandonment for the assay of abiding hepatitis B. The Hepatitis Interventional Assay Group. N. Engl. J. Med. 323, 295–301 (1990).

CAS  PubMed  Google Scholar 

Solal-Celigny, P. et al. Recombinant interferon α-2b accumulated with a dieting absolute doxorubicin in patients with avant-garde follicular lymphoma. Groupe d’Etude des Lymphomes de l’Adulte. N. Engl. J. Med. 329, 1608–1614 (1993).

CAS  PubMed  Google Scholar 

Manns, M. P. et al. Peginterferon α-2b additional ribavirin compared with interferon α-2b additional ribavirin for antecedent assay of abiding hepatitis C: a randomised trial. Lancet 358, 958–965 (2001).

CAS  Google Scholar 

Simon, D. M. et al. Assay of abiding hepatitis C with interferon α-n3: a multicenter, randomized, open-label trial. Hepatology 25, 445–448 (1997).

CAS  PubMed  Google Scholar 

Friedmankien, A. Management of condylomata acuminata with Alferon-N injection, interferon α-n3 (human-leukocyte derived). Am. J. Obstet. Gynecol. 172, 1359–1368 (1995).

CAS  Google Scholar 

Panitch, H. et al. Randomized, allusive abstraction of interferon β-1a assay regimens in MS: the EVIDENCE trial. Neurology 59, 1496–1506 (2002).

CAS  PubMed  Google Scholar 

Jacobs, L. D. et al. Intramuscular interferon β-1a assay accomplished during a aboriginal demyelinating accident in assorted sclerosis. CHAMPS Abstraction Group. N. Engl. J. Med. 343, 898–904 (2000).

CAS  PubMed  Google Scholar 

Byrne, E. Randomized, allusive abstraction of interferon β-1a assay regimens in MS: the EVIDENCE trial. Neurology 60, 1872–1873 (2003).

PubMed  Google Scholar 

No authors listed. Randomised double-blind placebo-controlled abstraction of interferon β-1a in relapsing/remitting assorted sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon β-1a Subcutaneously in Assorted Sclerosis) Abstraction Group. Lancet 352, 1498–1504 (1998).

Paty, D. W. & Li, D. K. Interferon β-1b is able in relapsing-remitting assorted sclerosis. II. MRI appraisal after-effects of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Abstraction Group and the IFNB Assorted Sclerosis Abstraction Group. Neurology 43, 662–667 (1993).

CAS  PubMed  Google Scholar 

No authors listed. Interferon β-1b in the assay of assorted sclerosis: final aftereffect of the randomized controlled trial. The IFNB Assorted Sclerosis Abstraction Group and The University of British Columbia MS/MRI Appraisal Group. Neurology 45, 1277–1285 (1995).

Durelli, L. et al. Every-other-day interferon β-1b adjoin once-weekly interferon β-1a for assorted sclerosis: after-effects of a 2-year -to-be randomised multicentre abstraction (INCOMIN). Lancet 359, 1453–1460 (2002).

CAS  PubMed  Google Scholar 

Raghu, G. et al. A placebo-controlled balloon of interferon γ-1b in patients with idiopathic pulmonary fibrosis. N. Engl. J. Med. 350, 125–133 (2004).

CAS  PubMed  Google Scholar 

Key, L. L. Jr et al. Abiding assay of osteopetrosis with recombinant beastly interferon γ. N. Engl. J. Med. 332, 1594–1599 (1995).

PubMed  Google Scholar 

Ezekowitz, R. A., Dinauer, M. C., Jaffe, H. S., Orkin, S. H. & Newburger, P. E. Partial alteration of the phagocyte birthmark in patients with X-linked abiding granulomatous ache by subcutaneous interferon γ. N. Engl. J. Med. 319, 146–151 (1988).

CAS  PubMed  Google Scholar 

Baron, S. et al. The interferons. Mechanisms of action and analytic applications. JAMA 266, 1375–1383 (1991).

CAS  PubMed  Google Scholar 

Key, L. L. Jr, Ries, W. L., Rodriguiz, R. M. & Hatcher, H. C. Recombinant beastly interferon γ assay for osteopetrosis. J. Pediatr. 121, 119–124 (1992).

PubMed  Google Scholar 

Negrier, S. et al. Recombinant beastly interleukin-2, recombinant beastly interferon α-2a, or both in metastatic renal-cell carcinoma. Groupe Francais d’Immunotherapie. N. Engl. J. Med. 338, 1272–1278 (1998).

CAS  PubMed  Google Scholar 

Atkins, M. B. et al. High-dose recombinant interleukin 2 assay for patients with metastatic melanoma: appraisal of 270 patients advised amid 1985 and 1993. J. Clin. Oncol. 17, 2105–2116 (1999).

CAS  Google Scholar 

Rosenberg, S. A. et al. Assay of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J. Natl Blight Inst. 86, 1159–1166 (1994).

CAS  PubMed  Google Scholar 

Atkins, M. B., Kunkel, L., Sznol, M. & Rosenberg, S. A. High-dose recombinant interleukin-2 assay in patients with metastatic melanoma: abiding adaptation update. Blight J. Sci. Am. 6 (Suppl. 1), 11–14 (2000).

Google Scholar 

Goldhaber, S. Z. et al. Randomized controlled balloon of recombinant tissue plasminogen-activator adjoin urokinase in the assay of astute pulmonary-embolism. Lancet 2, 293–298 (1988).

CAS  PubMed  Google Scholar 

Tow, D. E., Wagner, H. N. & Holmes, R. A. Urokinase in pulmonary embolism. N. Engl. J. Med. 277, 1161–1167 (1967).

CAS  PubMed  Google Scholar 

Chesnut, C. H. et al. A randomized balloon of nasal aerosol apricot calcitonin in postmenopausal women with accustomed osteoporosis: the anticipate ceremony of osteoporotic fractures study. Am. J. Med. 109, 267–276 (2000).

CAS  PubMed  Google Scholar 

Colman, E., Hedin, R., Swann, J. & Orloff, D. A abrupt history of calcitonin. Lancet 359, 885–886 (2002).

PubMed  Google Scholar 

Body, J. J. et al. A randomized double-blind balloon to analyze the ability of teriparatide [recombinant beastly parathyroid hormone (1–34)] with alendronate in postmenopausal women with osteoporosis. J. Clin. Endocrinol. Metab. 87, 4528–4535 (2002).

CAS  PubMed  Google Scholar 

Neer, R. M. et al. Effect of parathyroid hormone (1–34) on fractures and cartilage mineral body in postmenopausal women with osteoporosis. N. Engl. J. Med. 344, 1434–1441 (2001).

CAS  PubMed  Google Scholar 

Reeve, J. Recombinant beastly parathyroid hormone. BMJ 324, 435–436 (2002).

PubMed  PubMed Central  Google Scholar 

Tashjian, A. H. Jr. & Gagel, R. F. Teriparatide [human PTH(1–34)]: 2.5 years of acquaintance on the use and assurance of the biologic for the assay of osteoporosis. J. Cartilage Miner. Res. 21, 354–365 (2006).

CAS  Google Scholar 

Heine, R. J. et al. Exenatide adjoin insulin glargine in patients with suboptimally controlled blazon 2 diabetes: a randomized trial. Ann. Intern. Med. 143, 559–569 (2005).

CAS  PubMed  Google Scholar 

Tomassetti, P. et al. Assay of blazon II belly carcinoid tumors with somatostatin analogues. N. Engl. J. Med. 343, 551–554 (2000).

CAS  PubMed  Google Scholar 

Lamberts, S. W. J., van der Lely, A-. J., de Herder, W. W. & Hofland, L. J. Biologic assay — Octreotide. N. Engl. J. Med. 334, 246–254 (1996).

CAS  PubMed  Google Scholar 

Govender, S., Csimma, C., Genant, H. K. & Valentin-Opran, A. Recombinant beastly cartilage morphogenetic protein-2 for assay of accessible tibial fractures. A prospective, controlled, randomized abstraction of four hundred and fifty patients. J. Cartilage Joint Surg. Am. 84, 2123–2134 (2002).

PubMed  Google Scholar 

Boden, S. D., Zdeblick, T. A., Sandhu, H. S. & Heim, S. E. The use of rhBMP-2 in interbody admixture cages. Definitive affirmation of osteoinduction in humans: a basic report. Spine 25, 376–381 (2000).

CAS  PubMed  Google Scholar 

Friedlaender, G. E. et al. Osteogenic protein-1 (bone morphogenetic protein-7) in the assay of tibial nonunions. A prospective, randomized analytic balloon comparing rhOP-1 with beginning cartilage autograft. J. Cartilage Joint Surg. Am. 83, S151–S158 (2001).

PubMed  Google Scholar 

Feuillan, P. P., Jones, J. V., Barnes, K., Oerter-Klein, K. & Cutler, G. B. Changeable arbor afterwards cessation of gonadotropin-releasing hormone analog assay of girls with avant-garde puberty: continued appellation aftereffect comparing girls with hypothalamic hamartoma to those with idiopathic avant-garde puberty. J. Clin. Endocrinol. Metab. 84, 44–49 (1999).

CAS  PubMed  Google Scholar 

Jay, N. et al. Ovulation and menstrual action of boyish girls with axial avant-garde adolescence afterwards assay with gonadotropin-releasing-hormone agonists. J. Clin. Endocrinol. Metab. 75, 890–894 (1992).

CAS  PubMed  Google Scholar 

Spielberger, R. et al. Palifermin for articulate mucositis afterwards accelerated assay for hematologic cancers. N. Engl. J. Med. 351, 2590–2598 (2004).

CAS  PubMed  Google Scholar 

Smiell, J. M. et al. Ability and assurance of becaplermin (recombinant beastly platelet-derived advance factor-BB) in patients with nonhealing, lower acme diabetic ulcers: a accumulated appraisal of four randomized studies. Wound Repair Regen. 7, 335–346 (1999).

CAS  PubMed  Google Scholar 

Embil, J. M. et al. Recombinant beastly platelet-derived advance factor-BB (becaplermin) for healing abiding lower acme diabetic ulcers: an open-label analytic appraisal of efficacy. Wound Repair Regen. 8, 162–168 (2000).

CAS  PubMed  Google Scholar 

Wieman, T. J. Analytic ability of becaplermin (rhPDGF-BB) gel. Becaplermin Gel Studies Group. Am. J. Surg. 176, 74S–79S (1998).

CAS  PubMed  Google Scholar 

Hellgren, L. Cleansing backdrop of counterbalanced trypsin and streptokinase-streptodornase in baleful leg ulcers. Eur. J. Clin. Pharmacol. 24, 623–628 (1983).

CAS  PubMed  Google Scholar 

Intravenous nesiritide vs nitroglycerin for assay of decompensated congestive affection failure: a randomized controlled trial. JAMA 287, 1531–1540 (2002).

Colucci, W. S. et al. Intravenous nesiritide, a natriuretic peptide, in the assay of decompensated congestive affection failure. Nesiritide Abstraction Group. N. Engl. J. Med. 343, 246–253 (2000).

CAS  PubMed  Google Scholar 

Blasi, J. et al. Botulinum neurotoxin-a selectively cleaves the synaptic protein snap-25. Attributes 365, 160–163 (1993).

CAS  PubMed  Google Scholar 

Jankovic, J. & Brin, M. F. Ameliorative uses of botulinum toxin. N. Engl. J. Med. 324, 1186–1194 (1991).

CAS  PubMed  Google Scholar 

Schiavo, G. et al. Tetanus and botulinum-b neurotoxins block neurotransmitter absolution by proteolytic break of synaptobrevin. Attributes 359, 832–835 (1992).

CAS  PubMed  Google Scholar 

Patel, B. C. K. et al. A allegory of contemporary and retrobulbar anesthesia for avalanche surgery. Ophthalmology 103, 1196–1203 (1996).

CAS  PubMed  Google Scholar 

Aslam, S. et al. Effect of hyaluronidase on ocular action and eyelid action in sub-Tenon’s anaesthesia: randomised controlled trial. Eye 20, 579–582 (2006).

CAS  PubMed  Google Scholar 

Goldman, S. C. et al. A randomized allegory amid rasburicase and allopurinol in accouchement with lymphoma or leukemia at aerial accident for bump lysis. Claret 97, 2998–3003 (2001).

CAS  PubMed  Google Scholar 

Lincoff, A. M. et al. Bivalirudin and conditional glycoprotein IIb/IIIa barricade compared with heparin and planned glycoprotein IIb/IIIa barricade during percutaneous coronary action — REPLACE-2 Randomized Trial. JAMA 289, 853–863 (2003).

CAS  PubMed  Google Scholar 

Bittl, J. A. et al. Assay with bivalirudin (hirulog) as compared with heparin during coronary angioplasty for ambiguous or postinfarction angina. N. Engl. J. Med. 333, 764–769 (1995).

CAS  PubMed  Google Scholar 

The GUSTO Investigators. An all-embracing randomized balloon comparing four thrombolytic strategies for astute myocardial infarction. N. Engl. J. Med. 329, 673–682 (1993).

Hunt, D. et al. Isis-3 — a randomized allegory of streptokinase vs tissue plasminogen-activator vs anistreplase and of aspirin additional heparin vs aspirin abandoned amid 41,299 cases of doubtable astute myocardial-infarction. Lancet 339, 753–770 (1992).

Google Scholar 

Anderson, J. L. et al. Multicenter reperfusion balloon of intravenous anisoylated plasminogen streptokinase activator circuitous (APSAC) in astute myocardial-infarction — controlled allegory with intracoronary streptokinase. J. Am. Coll. Cardiol. 11, 1153–1163 (1988).

CAS  PubMed  Google Scholar 

Hurwitz, H. et al. Bevacizumab additional irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 350, 2335–2342 (2004).

CAS  Google Scholar 

Ferrara, N., Hillan, K. J., Gerber, H. P. & Novotny, W. Discovery and development of bevacizumab, an anti-VEGF antibiotic for alleviative cancer. Attributes Rev. Biologic Discov. 3, 391–400 (2004).

CAS  Google Scholar 

Yang, J. C. et al. A randomized balloon of bevacizumab, an anti-vascular endothelial advance agency antibody, for metastatic renal cancer. N. Engl. J. Med. 349, 427–434 (2003).

CAS  PubMed  PubMed Central  Google Scholar 

Kabbinavar, F. et al. Appearance II, randomized balloon comparing bevacizumab additional fluorouracil (FU)/leucovorin (LV) with FU/LV abandoned in patients with metastatic colorectal cancer. J. Clin. Oncol. 21, 60–65 (2003).

CAS  PubMed  Google Scholar 

Wainberg, Z. & Hecht, J. R. A appearance III randomized, open-label, controlled balloon of chemotherapy and bevacizumab with or afterwards panitumumab in the first-line assay of patients with metastatic colorectal cancer. Clin. Colorectal Blight 5, 363–367 (2006).

CAS  PubMed  Google Scholar 

Keating, M. J. et al. Ameliorative role of alemtuzumab (Campath-1H) in patients who accept bootless fludarabine: after-effects of a ample all-embracing study. Claret 99, 3554–3561 (2002).

CAS  PubMed  Google Scholar 

Keating, M. J. et al. Aboriginal after-effects of a chemoimmunotherapy dieting of fludarabine, cyclophosphamide, and rituximab as antecedent assay for abiding lymphocytic leukemia. J. Clin. Oncol. 23, 4079–4088 (2005).

CAS  PubMed  Google Scholar 

Di Gaetano, N. et al. Synergism amid fludarabine and rituximab appear in a follicular lymphoma corpuscle band aggressive to the, cytotoxic action of either biologic alone. Br. J. Haematology 114, 800–809 (2001).

CAS  Google Scholar 

Jazirehi, A. R., Huerta-Yepez, S., Cheng, G. H. & Bonavida, B. Rituximab (chimeric anti-CD20 monoclonal antibody) inhibits the basal nuclear factor-k B signaling alleyway in non-Hodgkin’s lymphoma B-cell lines: role in sensitization to chemotherapeutic drug-induced apoptosis. Blight Res. 65, 264–276 (2005).

CAS  PubMed  Google Scholar 

Genovese, M. C. et al. Abatacept for rheumatoid arthritis adverse to bump afterlife agency α inhibition. N. Engl. J. Med. 353, 1114–1123 (2005).

CAS  PubMed  PubMed Central  Google Scholar 

Cohen, S. B. et al. A multicenter double-blind randomized placebo-controlled balloon of Kineret (anakinra), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis advised with accomplishments methotrexate therapy. Ann. Rheum. Dis. 63, 1062–1068 (2004).

CAS  PubMed  PubMed Central  Google Scholar 

Fleischmann, R. M. et al. Anakinra, a recombinant beastly interleukin-1 receptor adversary (r-metHuIL-1ra), in patients with rheumatoid arthritis: a large, international, multicenter, placebo-controlled trial. Arthritis Rheum. 48, 927–934 (2003).

CAS  PubMed  Google Scholar 

Tesser, J. et al. Accessory medication use in a large, international, multicenter, placebo controlled balloon of anakinra, a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis. J. Rheumatol. 31, 649–654 (2004).

CAS  PubMed  Google Scholar 

Olsen, N. J. & Stein, C. M. Biologic assay — new drugs for rheumatoid arthritis. N. Engl. J. Med. 350, 2167–2179 (2004).

CAS  PubMed  Google Scholar 

Weinblatt, M. E. et al. Adalimumab, a absolutely beastly anti-tumor afterlife agency a monoclonal antibody, for the assay of rheumatoid arthritis in patients demography accessory methotrexate — The ARMADA trial. Arthritis Rheum. 48, 35–45 (2003).

CAS  PubMed  Google Scholar 

Ellis, C. N. & Krueger, G. G. Assay of abiding applique crawling by careful targeting of anamnesis effector T lymphocytes. N. Engl. J. Med. 345, 248–255 (2001).

CAS  PubMed  Google Scholar 

Krueger, G. G. et al. A randomized, double-blind, placebo-controlled appearance III abstraction evaluating ability and tolerability of 2 courses of alefacept in patients with abiding applique psoriasis. J. Am. Acad. Dermatol. 47, 821–833 (2002).

PubMed  Google Scholar 

Lebwohl, M. et al. A atypical targeted T-cell modulator, efalizumab, for applique psoriasis. N. Engl. J. Med. 349, 2004–2013 (2003).

CAS  PubMed  Google Scholar 

Gordon, K. B. et al. Efalizumab for patients with abstinent to astringent applique psoriasis: a randomized controlled trial. JAMA 290, 3073–3080 (2003).

CAS  PubMed  Google Scholar 

Miller, D. H. et al. A controlled balloon of natalizumab for relapsing assorted sclerosis. N. Engl. J. Med. 348, 15–23 (2003).

CAS  PubMed  Google Scholar 

Hillmen, P. et al. Effect of eculizumab on hemolysis and admixture requirements in patients with paroxysmal nocturnal hemoglobinuria. N. Engl. J. Med. 350, 552–559 (2004).

CAS  PubMed  PubMed Central  Google Scholar 

Hillmen, P. et al. The accompaniment inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N. Engl. J. Med. 355, 1233–1243 (2006).

CAS  PubMed  PubMed Central  Google Scholar 

Denton, M. D., Magee, C. C. & Sayegh, M. H. Immunosuppressive strategies in transplantation. Lancet 353, 1083–1091 (1999).

CAS  PubMed  Google Scholar 

Frickhofen, N. et al. Assay of aplastic-anemia with antilymphocyte globulin and methylprednisolone with or afterwards cyclosporine. N. Engl. J. Med. 324, 1297–1304 (1991).

CAS  PubMed  Google Scholar 

Soulillou, J. P. et al. Randomized controlled balloon of a monoclonal-antibody adjoin the interleukin-2 receptor (33b3.1) as compared with aerial antithymocyte globulin for prophylaxis adjoin bounce of renal-allografts. N. Engl. J. Med. 322, 1175–1182 (1990).

CAS  PubMed  Google Scholar 

Nashan, B. et al. Randomised balloon of basiliximab adjoin placebo for ascendancy of astute cellular bounce in renal allograft recipients. CHIB 201 All-embracing Abstraction Group. Lancet 350, 1193–1198 (1997).

CAS  PubMed  Google Scholar 

Vincenti, F. et al. Interleukin-2-receptor barricade with daclizumab to anticipate astute bounce in renal transplantation. Daclizumab Triple Assay Abstraction Group. N. Engl. J. Med. 338, 161–165 (1998).

CAS  PubMed  Google Scholar 

No authors listed. A allegory of tacrolimus (FK 506) and cyclosporine for immunosuppression in alarmist transplantation. The U.S. Multicenter FK506 Alarmist Abstraction Group. N. Engl. J. Med. 331, 1110–1115 (1994).

Cosimi, A. B. et al. Assay of astute renal allograft bounce with OKT3 monoclonal antibody. Transplantation 32, 535–539 (1981).

CAS  PubMed  Google Scholar 

Cosimi, A. B. et al. A randomized analytic balloon comparing OKT3 and steroids for assay of hepatic allograft rejection. Transplantation 43, 91–95 (1987).

CAS  PubMed  Google Scholar 

Busse, W. et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the assay of astringent allergic asthma. J. Allergy Clin. Immunol. 108, 184–190 (2001).

CAS  PubMed  Google Scholar 

Casale, T. B. et al. Effect of omalizumab on affection of melancholia allergic rhinitis: a randomized controlled trial. JAMA 286, 2956–2967 (2001).

CAS  PubMed  Google Scholar 

Milgrom, H. et al. Assay of adolescence asthma with anti-immunoglobulin E antibiotic (omalizumab). Pediatrics 108, e36 (2001).

CAS  PubMed  Google Scholar 

No authors listed. Randomised placebo-controlled balloon of abciximab afore and during coronary action in adverse ambiguous angina: the CAPTURE Study. Lancet 349, 1429–1435 (1997).

Antman, E. M. et al. Abciximab facilitates the amount and admeasurement of thrombolysis: after-effects of the thrombolysis in myocardial infarction (TIMI) 14 trial. The TIMI 14 Investigators. Circulation 99, 2720–2732 (1999).

CAS  PubMed  Google Scholar 

Ibbotson, T., McGavin, J. K. & Goa, K. L. Abciximab: an adapted assay of its ameliorative use in patients with ischaemic affection ache ability percutaneous coronary revascularisation. Drugs 63, 1121–1163 (2003).

CAS  PubMed  Google Scholar 

Trainer, P. J. et al. Assay of acromegaly with the advance hormone-receptor adversary pegvisomant. N. Engl. J. Med. 342, 1171–1177 (2000).

CAS  PubMed  Google Scholar 

van der Lely, A. J. et al. Abiding assay of acromegaly with pegvisomant, a advance hormone receptor antagonist. Lancet 358, 1754–1759 (2001).

CAS  PubMed  Google Scholar 

Ruha, A. M. et al. Antecedent postmarketing acquaintance with Crotalidae polyvalent allowed Fab for assay of rattlesnake envenomation. Ann. Emerg. Med. 39, 609–615 (2002).

PubMed  Google Scholar 

Dart, R. C. & McNally, J. Efficacy, safety, and use of snake antivenoms in the United States. Ann. Emerg. Med. 37, 181–188 (2001).

CAS  PubMed  Google Scholar 

Smith, T. W., Haber, E., Yeatman, L. & Butler, V. P. Jr. Reversal of avant-garde digoxin beatitude with Fab bits of digoxin-specific antibodies. N. Engl. J. Med. 294, 797–800 (1976).

CAS  PubMed  Google Scholar 

Antman, E. M., Wenger, T. L., Butler, V. P. Jr, Haber, E. & Smith, T. W. Assay of 150 cases of life-threatening digitalis beatitude with digoxin-specific Fab antibiotic fragments. Final address of a multicenter study. Circulation 81, 1744–1752 (1990).

CAS  PubMed  PubMed Central  Google Scholar 

Brown, D. M. et al. Ranibizumab adjoin verteporfin for neovascular age-related macular degeneration. N. Engl. J. Med. 355, 1432–1444 (2006).

CAS  PubMed  Google Scholar 

Kaminski, M. S. et al. Radioimmunotherapy with iodine (131)I tositumomab for relapsed or adverse B-cell non-Hodgkin lymphoma: adapted after-effects and abiding aftereffect of the University of Michigan experience. Claret 96, 1259–1266 (2000).

CAS  PubMed  Google Scholar 

Press, O. W. et al. A appearance 2 balloon of CHOP chemotherapy followed by tositumomab/iodine I 131 tositumomab for ahead basic follicular non-Hodgkin lymphoma: Southwest Oncology Group Protocol S9911. Claret 102, 1606–1612 (2003).

CAS  PubMed  Google Scholar 

Aman, J. & Wranne, L. Hypoglycaemia in adolescence diabetes. II. Effect of subcutaneous or intramuscular bang of altered doses of glucagon. Acta Paediatr. Scand. 77, 548–553 (1988).

CAS  PubMed  Google Scholar 

Carson, M. J. & Koch, R. Analytic studies with glucagon in children. J. Pediatr. 47, 161–170 (1955).

CAS  PubMed  Google Scholar 

Jowell, P. S. et al. A double-blind, randomized, dosage acknowledgment abstraction testing the pharmacological ability of constructed beefy secretin. Aliment. Pharmacol. Ther. 14, 1679–1684 (2000).

CAS  PubMed  Google Scholar 

Somogyi, L., Ross, S. O., Cintron, M. & Toskes, P. P. Allegory of biologic beefy secretin, constructed beefy secretin, and constructed beastly secretin in pancreatic action testing. Pancreas 27, 230–234 (2003).

CAS  PubMed  Google Scholar 

Oberg, K. Neuroendocrine gastrointestinal tumours. Ann. Oncol. 7, 453–463 (1996).

CAS  PubMed  Google Scholar 

Maguire, R. T., Pascucci, V. L., Maroli, A. N. & Gulfo, J. V. Immunoscintigraphy in patients with colorectal, ovarian, and prostate-cancer — after-effects with site-specific immunoconjugates. Blight 72, 3453–3462 (1993).

CAS  PubMed  Google Scholar 

Hughes, K. et al. Use of carcinoembryonic antigen radioimmunodetection and computed tomography for admiration the resectability of alternate colorectal cancer. Ann. Surg. 226, 621–631 (1997).

CAS  PubMed  PubMed Central  Google Scholar 

Goldenberg, D. M. et al. Carcinoembryonic antigen immunoscintigraphy complements mammography in the assay of breast carcinoma. Blight 89, 104–115 (2000).

CAS  PubMed  Google Scholar 

Balaban, E. P. et al. Apprehension and staging of small-cell lung-carcinoma with a technetium-labeled monoclonal-antibody: a allegory with accepted staging methods. Clin. Nucl. Med. 17, 439–445 (1992).

CAS  PubMed  Google Scholar 

Johnson, L. L. et al. Antimyosin imaging in astute transmural myocardial infarctions — after-effects of a multicenter analytic trial. J. Am. Coll. Cardiol. 13, 27–35 (1989).

CAS  PubMed  Google Scholar 

Kipper, S. L. et al. Neutrophil-specific Tc-99m-labeled anti-CD15 monoclonal antibiotic imaging for assay of ambiguous appendicitis. J. Nucl. Med. 41, 449–455 (2000).

CAS  PubMed  Google Scholar 

Chapman, W. C., et al. A appearance 3, randomized, double-blind allusive abstraction of the ability and assurance of contemporary recombinant beastly thrombin and bovine thrombin in surgical hemostasis. J. Am. Coll. Surg. 205, 256–265 (2007).

PubMed  Google Scholar 

Food and Biologic Administering (FDA). Artefact Approval Information: Thrombin, Contemporary (Human), Adapted October 23, 2007. FDA web armpit [online], (2007).

Ri 2 Form 2 Why Ri 2 Form 2 Had Been So Popular Till Now? – ri 1040 form 2020
| Pleasant to help the blog, in this particular period I am going to demonstrate with regards to keyword. And from now on, here is the first photograph: